Table 2.
The characteristics according to the expression of topoisomerase‐II
| Topoisomerase‐II | |||
|---|---|---|---|
| Characteristic | High (n = 13) | Low (n = 31) | P‐value |
| Age | |||
| ≤66 | 5 | 17 | 0.51 |
| ≥67 | 8 | 14 | |
| Gender | |||
| Male | 9 | 21 | >0.99 |
| Female | 4 | 10 | |
| Smoking status | |||
| Smoker | 8 | 20 | >0.99 |
| Non‐smoker | 5 | 11 | |
| Stage | |||
| IIIA, IIIB | 0 | 7 | 0.09 |
| IV | 13 | 24 | |
| Histology | |||
| Adenocarcinoma | 9 | 22 | >0.99 |
| Nonadenocarcinoma | 4 | 9 | |
| Histology | |||
| Squamous cell carcinoma | 1 | 9 | 0.24 |
| Nonsquamous cell carcinoma | 12 | 22 | |
| PS | |||
| 0 | 6 | 16 | >0.99 |
| 1, 2 | 7 | 15 | |
| EGFR mutation status | |||
| mutation | 4 | 5 | 0.41 |
| wild‐type, unknown | 9 | 26 | |
| Response to first‐line treatment | |||
| CR, PR | 6 | 14 | >0.99 |
| SD, PD | 7 | 17 | |
| Number of regimens | |||
| <3 | 4 | 14 | 0.51 |
| ≥3 | 9 | 17 | |
| AMR, Number of cycles | |||
| <2 | 6 | 14 | >0.99 |
| ≥2 | 7 | 17 | |
| Response to AMR | |||
| PR | 2 | 2 | 0.57 |
| SD, PD | 11 | 29 | |
| Ki‐67 labeling index | |||
| <20 LI | 7 | 16 | >0.99 |
| ≥20 LI | 6 | 15 | |
AMR, amrubicin; CR, complete response; EGFR, epidermal growth factor receptor; LI, labeling index; PD, progressive disease; PR, partial response; PS, performance status; SD, stable disease.